Premium
Comparison between L ‐Dopa and lisuride intravenous infusions: A clinical study
Author(s) -
Ruggieri Stefano,
Stocchi Fabrizio,
Carta Angelico,
Bravi Daniele,
Bragoni Maura,
Giorgi Luigi,
Agnoli Alessandro
Publication year - 1988
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.870030405
Subject(s) - lisuride , levodopa , dopamine agonist , anesthesia , carbidopa , dopamine , parkinson's disease , medicine , dopaminergic , disease
L ‐Dopa is still the most effective drug for the treatment of Parkinson's Disease, but after 5 years or more of therapy fluctuations in motor performance and abnormal involuntary movements commonly appear. Continuous intravenous infusions of L ‐Dopa abolish or strikingly reduce such fluctuations. Unfortunately, this is not suitable for daily treatment because of the low solubility of L ‐Dopa. Lisuride is a potent dopamine agonist and is very soluble in water. In this study the clinical effects of L ‐Dopa and lisuride continuous intravenous infusions were compared in a group of 20 fluctuating parkinsonian patients L ‐Dopa controlled fluctuations in almost all the subjects, whereas only seven patients were continuously mobile while taking lisuride. Another seven patients showed a fluctuating response and the remaining six did not satisfactorily respond to lisuride. Dyskinesias were present in all patients during “on” phases, with both levodopa and lisuride treatment.